Previous work has identified the cytokine interferon gamma (IFNγ) as a regulator of type II interferon inflammation in AD patients and mouse models of neurodegeneration (Mastrangelo et al, 2009; Wood et al, 2015; Zheng et al, 2016) and a potential driver of Siglec‐8 expression in eosinophils (Steinke et al, 2013). This evidence concerns the gene IFNG and Alzheimer disease.